These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2465955)

  • 1. Effect of verapamil on platelet aggregation.
    Glusa E
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):469-73. PubMed ID: 2465955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Ca2+-antagonistic vasodilators, diltiazem, nifedipine, perhexiline and verapamil, on platelet aggregation in vitro.
    Ono H; Kimura M
    Arzneimittelforschung; 1981; 31(7):1131-4. PubMed ID: 7196762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of human platelet functions by verapamil.
    Ikeda Y; Kikuchi M; Toyama K; Watanabe K; Ando Y
    Thromb Haemost; 1981 Apr; 45(2):158-61. PubMed ID: 6789494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of platelet aggregation by diltiazem. Comparison with verapamil and nifedipine and inhibitory potencies of diltiazem metabolites.
    Kiyomoto A; Sasaki Y; Odawara A; Morita T
    Circ Res; 1983 Feb; 52(2 Pt 2):I115-9. PubMed ID: 6831645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Verapamil is a potent inhibitor of 5-HT-induced platelet aggregation.
    Glusa E; Bevan J; Heptinstall S
    Thromb Res; 1989 Jul; 55(2):239-245. PubMed ID: 2528843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic interaction of epinephrine and calcium ionophore in platelet aggregation.
    Butt IF; Saeed SA; Waqar SN; Aslam M
    J Ayub Med Coll Abbottabad; 2005; 17(2):1-5. PubMed ID: 16092638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the calcium-entry blocking agent nifedipine on activation of human platelets and comparison with verapamil.
    Han P; Boatwright C; Ardlie NG
    Thromb Haemost; 1983 Aug; 50(2):513-7. PubMed ID: 6314581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of platelet function of antiarrhythmic drugs, verapamil and disopyramide.
    Han P; Boatwright C; Ardlie NG
    Thromb Haemost; 1982 Apr; 47(2):150-3. PubMed ID: 7101234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of some calcium antagonists on aggregation by adrenalin and serotonin and on alpha-adrenoceptor radioligand binding in human platelets.
    Vinge E; Andersson TL; Larsson B
    Acta Physiol Scand; 1988 Jul; 133(3):407-16. PubMed ID: 2906509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of 5-hydroxytryptamine-potentiated aggregation of human blood platelets by 5-hydroxytryptamine receptor-blocking agents.
    Glusa E; Markwardt F
    Biomed Biochim Acta; 1984; 43(2):215-20. PubMed ID: 6732757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of diltiazem and verapamil on ADP-induced rabbit platelet shape change and aggregation.
    Dehpour AR; Samadian T; Akhavan MM; Meysamee F; Delfan A
    Gen Pharmacol; 1995 Oct; 26(6):1295-9. PubMed ID: 7590122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of carvedilol, propranolol, and verapamil on in vitro platelet function in healthy volunteers.
    Gasser JA; Betterridge DJ
    J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S29-34. PubMed ID: 1721976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How can we inhibit 5-HT-induced platelet aggregation and why should we bother?
    Heptinstall S; Bevan J
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):475-8. PubMed ID: 2465956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Some characteristics of mouse platelet aggregation and a comparison of the activity of a range of compounds in mouse and human platelet-rich plasma in vitro.
    Nunn B
    Thromb Haemost; 1981 Feb; 45(1):1-5. PubMed ID: 7245119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory effects of diltiazem on platelet activation caused by ionophore A23187 plus ADP or epinephrine in subthreshold concentrations.
    Mehta P; Mehta J; Ostrowski N; Brigmon L
    J Lab Clin Med; 1983 Sep; 102(3):332-9. PubMed ID: 6411841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiaggregatory activity of N-methyl- and N-isobutyl-1,2-diphenyl ethanolamines in rat platelets.
    el Tahir KE; el-Naser MA; Ageel AM; el-Obeid HA; al-Rashood KA
    Arch Int Pharmacodyn Ther; 1990; 307():162-71. PubMed ID: 2095711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of verapamil and diltiazem on human platelet function.
    Addonizio VP; Fisher CA; Strauss JF; Wachtfogel YT; Colman RW; Josephson ME
    Am J Physiol; 1986 Mar; 250(3 Pt 2):H366-71. PubMed ID: 3006516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the serotonin antagonists, cyproheptadine, ketanserin and mianserin, on cyclic flow reductions in stenosed canine coronary arteries.
    Bush LR
    J Pharmacol Exp Ther; 1987 Feb; 240(2):674-82. PubMed ID: 3806419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of MN-9202 on platelet aggregation, 5-HT release, TXB2 synthesis, and calcium mobilization in rabbit platelets in vitro.
    Wang LL; Mei QB; Zhao DH; Guo ZA
    Acta Pharmacol Sin; 2000 Jul; 21(7):623-6. PubMed ID: 11360670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in platelet response to adenosine 5'-diphosphate caused by verapamil.
    Walkowiak B; Koziołkiewicz W; Michalec L; Pawłowska Z; Krzesłowska J; Cierniewski CS
    Pol J Pharmacol; 1996; 48(3):303-5. PubMed ID: 9112667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.